APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy

16 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

22 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

18 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

07 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)

03 Nov 2022 16:01:01 By Nasdaq GlobeNewswire

Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting

03 Nov 2022 09:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results

31 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

30 Sep 2022 17:30:00 By Nasdaq GlobeNewswire

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

30 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

12 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)

24 Aug 2022 08:00:02 By Nasdaq GlobeNewswire